Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chronic Myeloid Leukemia Treatment Market Size Changed, over the years?
The market size for treating chronic myeloid leukemia has witnessed a substantial growth in the past few years. The market, valued at $9.2 billion in 2024, is projected to rise to $9.76 billion in 2025, at a compound annual growth rate (CAGR) of 6.2%. The previous growth phase can be credited to an increase in chronic myeloid leukemia cases, greater consciousness about cancer therapy, government efforts, and burgeoning research and development endeavors aimed at chronic myeloid leukemia treatments.
How Much Will the Chronic Myeloid Leukemia Treatment Market Be Worth in 2029?
The market size of treatments for chronic myeloid leukemia is anticipated to experience considerable growth in the coming years. It is projected to rise to $13.12 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%. Increased demand for more effective and bearable treatments, heightened healthcare expenditure, investments in therapies for chronic myeloid leukemia, and personalized medicine’s growth contribute to this expected rise. In the forecasted period, key trends encompass better diagnosis and screening methods, innovative treatment approaches for chronic myeloid leukemia, the evolution of targeted therapies, advanced early diagnosis, screening technologies, and monitoring.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12915&type=smp
Which is the Largest Company in the Chronic Myeloid Leukemia Treatment Market?
Major companies operating in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.
What Are the Main Market Drivers in the Chronic Myeloid Leukemia Treatment Industry?
The surge in myeloid leukemia instances is projected to spur the progression of the chronic myeloid leukemia (CML) treatment market. Originating in the bone marrow, myeloid leukemia is a cancer classification that impacts the cells tasked with the creation of various blood cell types. The main purpose of Chronic myeloid leukemia (CML) treatment is to boost the functionality of the bone marrow by tackling the underlying cause of leukemia, thereby lowering the risk associated with low blood cell count complications. Furthermore, it reduces the dependency on chemotherapy and transplants and enhances survival rates for myeloid leukemia individuals. For example, as per the American Cancer Society’s estimates in January 2023, in the United States, approximately 20,380 cases of acute myeloid leukemia (AML) were recorded in adults, along with 11,310 deaths in 2023. Thus, the escalating incidences of myeloid leukemia steer the growth of the chronic myeloid leukemia (CML) treatment market. Rapid growth in the CML treatment market is predicted due to the escalating incidences of chromosome abnormalities. These abnormalities pertain to structural or numeric defects in a person’s chromosomes, which are the threads within cells that harbor genetic data. Patients with certain chromosomal abnormalities can often have a poor prognosis and require more intensive treatments like CML. A case in point is a study carried out in Saudi Arabia, published by the National Library of Medicine (NLM), a U.S-based biomedical informatics and computational health data science researcher. It revealed that chromosome abnormalities were present in 59 newborns suffering from congenital anomalies (accounting for 39.3%), which constituted 2.3% of total Neonatal Intensive Care Unit (NICU) admissions. Therefore, the growing occurrence of chromosome abnormalities is aiding the growth of the chronic myeloid leukemia (CML) treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12915&type=smp
How Is the Chronic Myeloid Leukemia Treatment Market Segments Structured?
The chronic myeloid leukemia treatment market covered in this report is segmented –
1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Route of Administration: Oral, Parenteral, Other Route of Administrations
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies
2) By Chemotherapy: Combination Chemotherapy, Single-Agent Chemotherapy
3) By Radiation Therapy: External Beam Radiation Therapy, Total Body Irradiation
4) By Splenectomy: Open Splenectomy, Laparoscopic Splenectomy
5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
What Strategic Trends Are Transforming the Chronic Myeloid Leukemia Treatment Market?
Key businesses in the chronic myeloid leukemia (CML) treatment sector are concentrating their efforts on the creation of novel items to maintain market prominence. For example, Precipio, Inc., a cancer diagnostic firm based out of the United States, released the BCR-ABL 2.0 Panel for chronic myeloid leukemia (CML) in August 2023. This instrument pinpoints the BCR-ABL1 gene and aids in the diagnosis of chronic myeloid leukemia (CML). It represents the most state-of-the-art BCR-ABL panel, providing comprehensive coverage, simplified workflow and lower expenses while improving patient care. It also incorporates the ability to identify the ABL1 mutation, thereby eliminating the necessity for an additional round of BCR-ABL1 gene testing, offering highly precise outcomes.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Chronic Myeloid Leukemia Treatment Market?
North America was the largest region in the chronic myeloid leukemia treatment market in 2024. The regions covered in chronic myeloid leukemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12915
This Report Delivers Insight On:
1. How big is the chronic myeloid leukemia treatment market, and how is it changing globally?
2. Who are the major companies in the chronic myeloid leukemia treatment market, and how are they performing?
3. What are the key opportunities and risks in the chronic myeloid leukemia treatment market right now?
4. Which products or customer segments are growing the most in the chronic myeloid leukemia treatment market?
5. What factors are helping or slowing down the growth of the chronic myeloid leukemia treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
